Why South San Francisco Home Prices Stay Strong Despite Biotech

Genentech cut a group of vice presidents from its research division in June 2026, then followed with a WARN notice affecting 103 more employees at its South San Francisco headquarters, effective July 29. Pfizer shut its research site at 181 Oyster Point Boulevard entirely by the end of April 2026, walking away from roughly 164,000 square feet it had already tried and failed to sublease. Bay Area life-science vacancy sat near 30 percent late last year, a striking number for a submarket built almost entirely around the industry that gave this city its name.

None of that shows up in the home price data. Over the three months ending May 2026, South San Francisco's median sale price ran $1.3 million, up 5.1 percent from the same period a year earlier, with homes still moving in about 14 days and drawing an average of six offers. If you were reading only the employment headlines, you'd expect a city bracing for a correction. If you were reading only the sale prices, you'd assume the biotech sector was having its best year yet. Both readings are accurate. The gap between them is the actual story, and it changes how you should think about buying or comparing this market against its Peninsula neighbors.

The Layoffs Are Concentrated, Not Diffuse

The 2026 cuts at Genentech and the Pfizer closure both trace back to the same commercial reality: large, single-tenant lab space has gotten harder to justify. Pfizer's Oyster Point site had been the headquarters of Global Blood Therapeutics before Pfizer acquired that company for about $5.4 billion in 2022. Roughly four years later, the company called the space underutilized, shifted the remaining staff to remote roles, and closed the door. That is a specific commercial real estate decision about one large building on one waterfront campus, not a referendum on the industry as a whole. Brokers covering the sector have noted that smaller biotech tenants, the ones looking for 5,000 to 20,000 square feet, are still actively searching for space. The weakness sits almost entirely in the giant blocks that companies signed during the pandemic-era expansion and now can't fill.

That distinction matters because it tells you where the pain is landing. It's landing on commercial landlords and on a specific slice of the workforce tied to those oversized leases. It is not landing evenly across every household that happens to live in South San Francisco.

Where the Disconnect Actually Comes From

The city commissioned its own anti-displacement study a few years ago, looking at what happened to housing costs and incomes as the area east of Highway 101 transformed from heavy industry into a global biotech cluster. The study found that between 2012 and 2022, home values and rents rose by more than 80 percent, landing around $1.1 million, while median household income in the city rose 67.5 percent over the same stretch. Those two numbers moving together looks like exactly what you'd expect from a boomtown.

Then the study found the detail that explains everything else:

Nearly 85 percent of new R&D jobs created in South San Francisco are held by people who do not live in South San Francisco.

That single fact decouples local employment swings from local housing demand more than most buyers assume. The scientists and researchers affected by this year's layoffs mostly commute in from somewhere else, whether that's BART from the city, Caltrain from further down the Peninsula, or a company shuttle from a neighborhood they can actually afford. When a lab cuts headcount, the immediate effect lands on that commuter base first, spread across dozens of zip codes. It does not concentrate into a wave of South San Francisco listings the way a single-employer factory town would feel a plant closure.

The same pattern is playing out just up the road. Gilead Sciences is cutting 108 positions at its Redwood City headquarters effective June 30, 2026, the latest round in a series of moves that has already seen the company shift biologics manufacturing roles out of a Southern California site and into Foster City. Jobs are moving between addresses inside the same industry without necessarily moving the people who hold them into or out of any particular neighborhood's housing stock.

What Is Actually Setting the Price

If biotech employment isn't the main driver of South San Francisco home values, something else has to be doing the work. Two forces show up consistently in the data, and neither one is about lab space at all.

The first is relative position. San Francisco's median sale price ran $1.7 million over the same three-month window, up 16.1 percent year over year. Typical home values in South San Francisco sit meaningfully below the broader San Mateo County median. For a buyer priced out of the city or out of Burlingame, South San Francisco offers the same electrified Caltrain line into San Francisco's 4th and King station, roughly 20 minutes on an express run, at a lower entry point. That spillover demand doesn't care what Genentech's headcount looks like this quarter. It cares about the gap between what San Francisco costs and what South San Francisco costs.

The second is inventory that simply isn't turning over. A meaningful share of current owners bought years ago and have shown no urgency to sell into a market they'd have to re-buy into at today's rates. That kind of holding pattern keeps resale supply thin almost regardless of what's happening on the commercial side of town, and thin supply is a more reliable price support than any single employer's earnings call.

The City Doesn't Behave the Same Way Everywhere

Zoom into specific pockets and the picture gets more useful for anyone actually comparing neighborhoods rather than reading a citywide average.

Downtown, centered on Grand Avenue, has absorbed the most new construction, with more than 1,500 units built since 2015 alongside the historic retail corridor's taquerias, Filipino bakeries, and the rebuilt Caltrain station. That station reconstruction, a $96.6 million project funded jointly by the city, San Mateo County Transportation Authority, and federal transit dollars, gave the area a 700-foot center-boarding platform and eliminated the old cross-track walk. New supply downtown means more price variation by building age and finish than you'd find in the settled single-family blocks nearby.

Sunshine Gardens and Sign Hill run in the opposite direction. Sunshine Gardens is mostly 1950s and 60s ranch homes, many with in-law units, sitting near the BART station and within walking distance of a Trader Joe's, a Costco, and the Kaiser Permanente medical campus. Sign Hill is steeper, quieter, and almost entirely owner-occupied, with trails into Sign Hill Park starting at the top of the neighborhood. Neither pocket has much rental or resale churn, which means listings there behave more like estate sales than market signals.

Westborough, west of Interstate 280, holds a different kind of buyer entirely. Built out mostly between the 1960s and 1980s around the Westborough Shopping Center, it trades commute convenience for more space per dollar, which is exactly the calculation a buyer makes when Downtown or Sign Hill pricing doesn't pencil out.

What This Means If You're Weighing This City Right Now

For a buyer comparing South San Francisco against San Mateo, Belmont, or Foster City, the practical takeaway is that this year's biotech headlines are not a reliable price signal here the way they might be in a company town built around one employer. The commuter structure of the local workforce absorbs employment shocks before they reach the resale market. That doesn't mean the market is immune to everything. It means the relevant variables are relative affordability against San Francisco, the pace of new downtown construction, and how long current owners intend to hold, not the quarterly layoff tracker.

For a seller, the same logic cuts the other way. Two similar homes in this city can post very different results depending on condition and pricing discipline, regardless of what's happening at the nearest lab campus. A well-prepared, accurately priced listing in a low-turnover pocket like Sign Hill or Sunshine Gardens can still draw multiple offers in a matter of days, because the buyer pool here has never been as narrowly tied to biotech payrolls as the city's identity might suggest.

A Few Questions Worth Answering Directly

Does a biotech layoff mean South San Francisco home prices will fall? Not on its own. The data through May 2026 shows median prices still rising year over year even as the sector absorbed real job cuts. The disconnect exists because most affected workers commute from elsewhere rather than compete for local listings.

Which part of the city is most exposed if lab vacancy stays high? The exposure sits with commercial landlords and downtown's newer mixed-use development, where office and retail vacancy could soften. Established single-family pockets with low owner turnover have shown much less sensitivity to commercial real estate cycles.

If you're trying to figure out what a specific South San Francisco address is actually worth against this backdrop, that's a conversation better had with numbers in front of you than headlines. Rick Lei brings a former CPA's read to exactly this kind of question, whether you're comparing this city against three others on your list or pricing a listing that needs to stand apart from the noise. Let's Connect.